Goy A et al. Phase II multicenter study of single-agent lenalidomide in subjects with mantle cell lymphoma who relapsed or progressed after or were refractory to bortezomib: The MCL-001 "EMERGE" study. Proc ASH 2012;Abstract 905.

Dr Kahl is Skoronski Chair of Lymphoma Research, Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.